Fine Mark National Bank & Trust Amgen Inc Transaction History

Fine Mark National Bank & Trust

$2.84 Billion
Q3 2024

A detailed history of Fine Mark National Bank & Trust transactions in Amgen Inc stock. As of the latest transaction made, Fine Mark National Bank & Trust holds 45,116 shares of AMGN stock, worth $11.9 Million. This represents 0.51% of its overall portfolio holdings.

Number of Shares

45,116

Previous 46,044 2.02%

Holding current value

$11.9 Million

Previous $14.4 Million 1.04%

% of portfolio

0.51%

Previous 0.53%

29 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 13, 2024	SELL	$309.38 - $337.38 $287,104 - $313,088	-928 Reduced 2.02%	45,116 $14.5 Million
Q2 2024 Aug 02, 2024	BUY	$262.75 - $319.31 $33,106 - $40,233	126 Added 0.27%	46,044 $14.4 Million
Q1 2024 May 14, 2024	SELL	$268.87 - $324.56 $102,439 - $123,657	-381 Reduced 0.82%	45,918 $13.1 Million
Q4 2023 Feb 09, 2024	BUY	$255.7 - $288.46 $129,895 - $146,537	508 Added 1.11%	46,299 $13.3 Million
Q3 2023 Nov 15, 2023	SELL	$218.65 - $271.46 $310,045 - $384,930	-1,418 Reduced 3.0%	45,791 $12.3 Million
Q2 2023 Aug 11, 2023	SELL	$214.27 - $253.37 $20,784 - $24,576	-97 Reduced 0.21%	47,209 $10.5 Million
Q1 2023 May 08, 2023	BUY	$225.79 - $275.2 $55,092 - $67,148	244 Added 0.52%	47,306 $11.4 Million
Q4 2022 Feb 09, 2023	SELL	$229.03 - $291.01 $963,300 - $1.22 Million	-4,206 Reduced 8.2%	47,062 $12.4 Million
Q3 2022 Nov 14, 2022	BUY	$224.46 - $253.15 $237,254 - $267,579	1,057 Added 2.11%	51,268 $11.6 Million
Q2 2022 Aug 09, 2022	BUY	$230.71 - $256.74 $407,664 - $453,659	1,767 Added 3.65%	50,211 $12.2 Million
Q1 2022 May 16, 2022	BUY	$219.27 - $242.57 $2.55 Million - $2.82 Million	11,614 Added 31.53%	48,444 $11.7 Million
Q4 2021 Feb 14, 2022	SELL	$198.88 - $227.6 $538,964 - $616,796	-2,710 Reduced 6.85%	36,830 $8.29 Million
Q3 2021 Nov 12, 2021	SELL	$212.27 - $248.7 $141,796 - $166,131	-668 Reduced 1.66%	39,540 $8.41 Million
Q2 2021 Aug 13, 2021	SELL	$233.58 - $259.14 $104,410 - $115,835	-447 Reduced 1.1%	40,208 $9.8 Million
Q1 2021 May 12, 2021	SELL	$221.91 - $258.6 $61,690 - $71,890	-278 Reduced 0.68%	40,655 $10.1 Million
Q4 2020 Feb 10, 2021	SELL	$216.38 - $257.67 $219,842 - $261,792	-1,016 Reduced 2.42%	40,933 $9.41 Million
Q3 2020 Nov 12, 2020	SELL	$234.65 - $260.95 $170,355 - $189,449	-726 Reduced 1.7%	41,949 $10.7 Million
Q2 2020 Aug 13, 2020	BUY	$197.81 - $242.74 $163,588 - $200,745	827 Added 1.98%	42,675 $10.1 Million
Q1 2020 May 06, 2020	BUY	$182.24 - $241.7 $41,915 - $55,591	230 Added 0.55%	41,848 $8.48 Million
Q4 2019 Feb 07, 2020	BUY	$189.21 - $243.2 $288,923 - $371,366	1,527 Added 3.81%	41,618 $10 Million
Q3 2019 Nov 08, 2019	SELL	$174.11 - $208.62 $166,797 - $199,857	-958 Reduced 2.33%	40,091 $7.76 Million
Q2 2019 Aug 08, 2019	BUY	$166.7 - $195.41 $352,070 - $412,705	2,112 Added 5.42%	41,049 $7.57 Million
Q1 2019 May 07, 2019	BUY	$180.87 - $203.88 $267,506 - $301,538	1,479 Added 3.95%	38,937 $7.4 Million
Q4 2018 Feb 07, 2019	BUY	$178.4 - $208.25 $264,032 - $308,210	1,480 Added 4.11%	37,458 $7.29 Million
Q3 2018 Nov 02, 2018	BUY	$185.29 - $208.89 $102,465 - $115,516	553 Added 1.56%	35,978 $7.46 Million
Q2 2018 Aug 03, 2018	BUY	$166.05 - $186.51 $206,400 - $231,831	1,243 Added 3.64%	35,425 $6.54 Million
Q1 2018 Apr 26, 2018	BUY	$169.43 - $198.0 $300,060 - $350,658	1,771 Added 5.46%	34,182 $5.83 Million
Q4 2017 Jan 30, 2018	BUY	$168.79 - $188.59 $257,573 - $287,788	1,526 Added 4.94%	32,411 $5.64 Million
Q3 2017 Oct 30, 2017	BUY	$167.29 - $191.0 $5.17 Million - $5.9 Million	30,885	30,885 $5.76 Million

Others Institutions Holding AMGN

# of Institutions

3,125

Shares Held

409M

Call Options Held

7.56M

Put Options Held

7.2M

View Full List

About AMGEN INC

Ticker AMGN
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 534,931,008
Market Cap $141B
Description
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces th...

More about AMGN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Fine Mark National Bank & Trust, based on Form 13F filings with the SEC.

News

Stay updated on Fine Mark National Bank & Trust with notifications on news.

Account

Fine Mark National Bank & Trust Amgen Inc Transaction History